
News and Events
News From Inside
FyoniBio collaborates with BioLamina and Alder Therapeutics

FyoniBio, Alder Therapeutics, and BioLamina enter Consortium Grant Agreement to Propel Recombinant Human Laminin Development for Clinical Applications.
FyoniBio gets CIR accreditation

We are pleased to announce that FyoniBio has received CIR (Crédit d’Impôt Recherche or CIR) accreditation for three years until 2025, which will benefit our French clientele.
Launch of FyoniBio’s CHOFlow® Technology

CHOFlow®: Our high yield expression technology for afucosylated ADCC enhanced antibodies and beyond.
Successful Cell Line Development for Strike Pharma

Strike Pharma and FyoniBio Conclude Successfully Cell Line Development of Strike’s Bi-specific Antibody and Clinical Lead Candidate.
Service Agreement with adivo

FyoniBio and adivo GmbH sign a Service Agreement covering the generation of a production cell line for their canine therapeutic mAb candidate
Cooperation with Strike Pharma

We have signed a Master Service Agreement with Strike Pharma covering the cell line development for a novel bi-specific therapeutic mAb.
Partnership with ProteoNic

We have signed a license agreement for using ProteoNic’s 2G Unic™ technology in our cell line development platform.
Launch of FyoniBio GmbH

The FyoniBio service branch of Glycotope GmbH will continue its business as FyoniBio GmbH.
Cooperation with BioGenes

BioGenes and FyoniBio begin a cooperation for Pharmacokinetic & Immunogenicity Analyses
Collaboration with CSL Behring

We are happy to have initiated a collaboration with CSL Behring research division.
Current and Upcoming Events
NextGen Biomed

Meet FyoniBio at NextGen Biomed 2025 conference in London, UK!
This leading conference unites experts, researchers, and industry professionals to explore groundbreaking advancements in biologics, with a focus on the latest trends and innovations in drug discovery and therapeutic development.
12–14 March 2025
BIO-Europe Spring

FyoniBio is participating in BIO-Europe Spring 2025, Europe’s premier springtime partnering event for the global life science industry. Join us to discover new opportunities of biotech industry together!
17–19 March 2025
Bioprocessing Summit Europe

Join FyoniBio at Bioprocessing Summit Europe in Barcelona, Spain! This event unites 750+ experts in upstream, downstream, bioproduction, and analytics to drive innovation in biologics and genetic therapy manufacturing, quality, and control.
18–20 March 2025